## Practitioner's Docket No. MPI01-019P1RNM

## **REMARKS**

This Amendment After Allowance under 37 C.F.R. §1.312 is being presented to correct informalities in the Specification. The Specification has been amended to delete blank spaces. The claim scope has not been altered and no new matter has been added. Claims 1-7, 12 and 23-25 are pending.

## **CONCLUSION**

In view of the above amendments and remarks, it is believed that the application is in condition to be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

This paper is being filed timely as the issue fee is being paid concurrently herewith. No extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

14 April 2005

MILLENNIUM PHARMACEUTICALS, INC.

Tracy M. Sioussat, Ph.D.

Registration No. 50,609

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-374-7679 Facsimile - 617-551-8820